- Home
- DHAI vs TARA Comparison
DHAI vs TARA Comparison
Compare DHAI & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHAI
- TARA
- Stock Information
- Founded
- DHAI 2007
- TARA N/A
- Country
- DHAI United States
- TARA United States
- Employees
- DHAI N/A
- TARA N/A
- Industry
- DHAI
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DHAI
- TARA Health Care
- Exchange
- DHAI NYSE
- TARA Nasdaq
- Market Cap
- DHAI 55.5M
- TARA 52.4M
- IPO Year
- DHAI N/A
- TARA N/A
- Fundamental
- Price
- DHAI $1.36
- TARA $5.04
- Analyst Decision
- DHAI
- TARA Strong Buy
- Analyst Count
- DHAI 0
- TARA 3
- Target Price
- DHAI N/A
- TARA $22.67
- AVG Volume (30 Days)
- DHAI 64.9K
- TARA 6.6M
- Earning Date
- DHAI 11-14-2024
- TARA 11-12-2024
- Dividend Yield
- DHAI N/A
- TARA N/A
- EPS Growth
- DHAI N/A
- TARA N/A
- EPS
- DHAI N/A
- TARA N/A
- Revenue
- DHAI $73,490,000.00
- TARA N/A
- Revenue This Year
- DHAI N/A
- TARA N/A
- Revenue Next Year
- DHAI N/A
- TARA N/A
- P/E Ratio
- DHAI N/A
- TARA N/A
- Revenue Growth
- DHAI 16.95
- TARA N/A
- 52 Week Low
- DHAI $0.72
- TARA $1.60
- 52 Week High
- DHAI $3.67
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- DHAI 51.20
- TARA 63.59
- Support Level
- DHAI $1.25
- TARA $5.27
- Resistance Level
- DHAI $2.00
- TARA $6.39
- Average True Range (ATR)
- DHAI 0.24
- TARA 0.89
- MACD
- DHAI 0.00
- TARA 0.05
- Stochastic Oscillator
- DHAI 25.97
- TARA 36.25
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).